Tofacitinib in Patients with Ulcerative Colitis: Inflammatory Bowel Disease Questionnaire Items in Phase 3 Randomized Controlled Induction Studies
Joseph Cappelleri
Inflammatory Bowel Diseases, 2020
View PDFchevron_right
Improvements in Disease Activity Partially Mediate the Effect of Tofacitinib Treatment on Generic and Disease-Specific Health-Related Quality of Life in Patients with Ulcerative Colitis: Data from the OCTAVE Program
Joseph Cappelleri
Digestive Diseases
View PDFchevron_right
Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial
Sean Gardiner
2020
View PDFchevron_right
Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes
Joseph Cappelleri
BMC Gastroenterology, 2015
View PDFchevron_right
Direct and Indirect Effects of Tofacitinib on Treatment Satisfaction in Patients with Ulcerative Colitis
Joseph Cappelleri
Journal of Crohn's and Colitis, 2016
View PDFchevron_right
Characteristics, clinical outcomes and patient-reported outcomes of patients with ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European countries
Joseph Cappelleri
BMC Gastroenterology, 2023
View PDFchevron_right
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis
William Sandborn
View PDFchevron_right
Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting
Bruce Salzberg MD, FACG
Inflammatory Bowel Diseases
View PDFchevron_right
Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A Brazilian Observational Multicentric Study
Fábio V. Teixeira
Crohn's & Colitis 360
View PDFchevron_right
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
Dahong Yu
The New England journal of medicine, 2017
View PDFchevron_right
Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program
Gosford Sawyerr
Inflammatory Bowel Diseases
View PDFchevron_right
P286 Sustained improvement in health-related quality of life outcomes in patients with Ulcerative Colitis with long-term tofacitinib treatment in the open-label extension study, OCTAVE Open
Sean Gardiner
Journal of Crohn's and Colitis, 2022
View PDFchevron_right
Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study
Csilla Keresztes
Inflammatory Bowel Diseases
View PDFchevron_right
P186 Impact of tofacitinib maintenance therapy on key Ulcerative Colitis patient-reported outcomes of fatigue, urgency, abdominal pain and sexual dysfunction using IBDQ and SF-36 individual items as proxies
Sean Gardiner
Journal of Crohn's and Colitis, 2023
View PDFchevron_right
Efficacy and Safety of Tofacitinib for Treatment of Moderate to Severe Active Ulcerative Colitis: First Report from Iran
Homayoon Vahedi
Archives of Iranian medicine, 2021
View PDFchevron_right
P334 Impact of disease duration on tofacitinib efficacy in patients with ulcerative colitis
ES Maller
Journal of Crohn's and Colitis, 2020
View PDFchevron_right
Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
ES Maller
Alimentary Pharmacology & Therapeutics
View PDFchevron_right
Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation
Natalie Bohm
BMJ Open Gastroenterology
View PDFchevron_right
Disease Burden and Patient-Reported Outcomes Among Ulcerative Colitis Patients According to Therapy at Enrollment Into CorEvitas’ Inflammatory Bowel Disease Registry
Vipin Arora
Crohn's & Colitis 360, 2022
View PDFchevron_right
Long-term safety and tolerability of oral tofacitinib in patients with Crohn’s disease: results from a phase 2, open-label, 48-week extension study
ES Maller
Alimentary Pharmacology & Therapeutics, 2019
View PDFchevron_right
Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis
ES Maller
Therapeutic Advances in Gastroenterology
View PDFchevron_right
A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
Glenn L Gordon MD
Clinical Gastroenterology and Hepatology, 2014
View PDFchevron_right
P781 Treatment outcome of tofacitinib dose reduction to 5 mg BID vs remaining on 10 mg BID in patients with Ulcerative Colitis who were in stable remission on 10 mg BID: Updated 30-month data from the double-blind, randomised RIVETING study
Sean Gardiner
Journal of Crohn's and Colitis, 2023
View PDFchevron_right
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
ES Maller
Gut, 2017
View PDFchevron_right
Quality of Life in Patients with Acute Severe Ulcerative Colitis: Long-Term Follow-Up Results from the CONSTRUCT Trial
Professor Laith Al-Rubaiy PhD, FRCP
Journal of Personalized Medicine
View PDFchevron_right
P550 Characterisation of hospitalised patients with ulcerative colitis treated with tofacitinib in the OCTAVE clinical programme for up to 7.8 years
Sean Gardiner
Journal of Crohn's and Colitis, 2023
View PDFchevron_right
Further Validation of the Crohn’s and Ulcerative Colitis Ques-tionnaire-32 (CUCQ-32) to Measure the Quality of Life in Pa-tients Treated with Biologics Therapy
Professor Laith Al-Rubaiy PhD, FRCP
View PDFchevron_right
Comparing Patient Reported Outcomes among Anti-TNF Experienced Patients with Ulcerative Colitis Initiating Vedolizumab versus Tofacitinib
Alan Kaul
Crohn's & colitis 360, 2023
View PDFchevron_right
Tofacitinib: An Option for Acute Severe Ulcerative Colitis?
Guilherme Simões
GE - Portuguese Journal of Gastroenterology
View PDFchevron_right
P571 Vedolizumab (VDZ) real-world outcomes in ulcerative colitis (UC)
Jakob Begun
Journal of Crohn's and Colitis, 2018
View PDFchevron_right
Tofacitinib Treatment is Associated with Modest and Reversible Increases in Serum Lipids in Patients with Ulcerative Colitis
Pam Taub
Clinical Gastroenterology and Hepatology
View PDFchevron_right
Delayed and limited administration of the JAKinib tofacitinib mitigates chronic DSS-induced colitis
Friederike Berberich-siebelt
Frontiers in Immunology
View PDFchevron_right
Rates of clinical remission and inadequate response to advanced therapies among patients with ulcerative colitis in Germany
Nils Picker
International Journal of Colorectal Disease
View PDFchevron_right
Disease Activity and Health-related Quality of Life Relationships with Work Productivity in Patients with Ulcerative Colitis in OCTAVE Induction 1 and 2 and OCTAVE Sustain
Sean Gardiner
Journal of Crohn's and Colitis
View PDFchevron_right
Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - Multicenter European cohort study
Gerassimos Mantzaris
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2016
View PDFchevron_right